Steno‐sphere: Navigating the enigmatic world of emerging multidrug‐resistantStenotrophomonas maltophilia
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Steno‐sphere: Navigating the enigmatic world of emerging multidrug‐resistantStenotrophomonas maltophilia
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-05-18
DOI
10.1002/phar.2828
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In vitro Time Kill of Trimethoprim/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli using Cation Adjusted Muller Hinton Broth and ISO-Sensitest Broth
- (2022) Maxwell J. Lasko et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Considerations for the Use of Phage Therapy in Clinical Practice
- (2022) Gina A. Suh et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: implications for susceptibility breakpoints
- (2022) Andrew J. Fratoni et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Real-World, Multicenter Evaluation of the Incidence and Risk Factors for Non-susceptible Stenotrophomonas maltophilia Isolates
- (2022) Bruce M. Jones et al. Journal of Global Antimicrobial Resistance
- Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals
- (2022) Sadia H Sarzynski et al. Open Forum Infectious Diseases
- Diagnostic Stewardship as a Team Sport: Interdisciplinary Perspectives on Improved Implementation of Interventions and Effect Measurement
- (2022) Kyle D. Hueth et al. Antibiotics-Basel
- Overcoming Stenotrophomonas maltophilia Resistance for a More Rational Therapeutic Approach
- (2022) Ravina Kullar et al. Open Forum Infectious Diseases
- Successful treatment of MDR Stenotrophomonas maltophilia-associated pneumonia with cefiderocol-based regimen in a patient with hematological malignancy
- (2022) Emanuela Zappulo et al. ANNALS OF HEMATOLOGY
- Trimethoprim/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model
- (2022) Maxwell J Lasko et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent
- (2022) Rima Fanaei Pirlar et al. Pharmaceutics
- Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia
- (2021) Ayesha Khan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structure, Assembly, and Function of Tripartite Efflux and Type 1 Secretion Systems in Gram-Negative Bacteria
- (2021) Ilyas Alav et al. CHEMICAL REVIEWS
- Emergence of fluoroquinolone resistance and possible mechanisms in clinical isolates of Stenotrophomonas maltophilia from Iran
- (2021) Akram Azimi et al. Scientific Reports
- StenoSCORE: Predicting Stenotrophomonas maltophilia Bloodstream Infections in the Hematologic Malignancy Population
- (2021) Sara M. Karaba et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy
- (2021) Shauna Jacobson Junco et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision
- (2021) Andrew J Fratoni et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia
- (2021) Ayesha Khan et al. JOURNAL OF CLINICAL MICROBIOLOGY
- The Potential of Phage Therapy against the Emerging Opportunistic Pathogen Stenotrophomonas maltophilia
- (2021) Jaclyn G. McCutcheon et al. Viruses-Basel
- Tigecycline in the Treatment of Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia: A Multicenter Retrospective Cohort Study
- (2021) Lei Zha et al. Infectious Diseases and Therapy
- In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
- (2021) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
- (2021) Pranita D Tamma et al. CLINICAL INFECTIOUS DISEASES
- Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
- (2020) Ahmed M Hamdi et al. Open Forum Infectious Diseases
- Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model
- (2020) Thomas P Lodise et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Burden of Bloodstream Infections due to Stenotrophomonas Maltophilia in the United States: A Large, Retrospective Database Study
- (2020) Bin Cai et al. Open Forum Infectious Diseases
- Genetic Variants of the DSF Quorum Sensing System in Stenotrophomonas maltophilia Influence Virulence and Resistance Phenotypes Among Genotypically Diverse Clinical Isolates
- (2020) Daniel Yero et al. Frontiers in Microbiology
- Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
- (2020) Gennaro De Pascale et al. Annals of Intensive Care
- Activity of aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against multidrug resistant Stenotrophomonas maltophilia
- (2020) M Biagi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital
- (2020) Zhongliang Duan et al. BMC MICROBIOLOGY
- Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
- (2020) Tiffany Luong et al. CLINICAL THERAPEUTICS
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- (2020) Richard G Wunderink et al. LANCET INFECTIOUS DISEASES
- Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States
- (2020) Saima Aslam et al. Open Forum Infectious Diseases
- Optimization of Aztreonam in Combination with Ceftazidime/Avibactam in a Cystic Fibrosis Patient with Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring
- (2020) Mallory C. Cowart et al. THERAPEUTIC DRUG MONITORING
- Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016)
- (2019) Ana C Gales et al. Open Forum Infectious Diseases
- Substantial Contribution of SmeDEF, SmeVWX, SmQnr, and Heat Shock Response to Fluoroquinolone Resistance in Clinical Isolates of Stenotrophomonas maltophilia
- (2019) Chao-Jung Wu et al. Frontiers in Microbiology
- Omadacycline: A Modernized Tetracycline
- (2019) Jason C Gallagher CLINICAL INFECTIOUS DISEASES
- Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States
- (2019) Maria F. Mojica et al. mBio
- In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus species complex, Stenotrophomonas maltophilia, and Burkholderia cepacia complex: Results from the SENTRY Antimicrobial Surveillance Program (2014-2018)
- (2019) Robert K. Flamm et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia infections
- (2019) Cara Nys et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Stenotrophomonas maltophilia biofilm: its role in infectious diseases
- (2019) Samantha Flores-Treviño et al. Expert Review of Anti-Infective Therapy
- Activity of potential alternative treatment agents for Stenotrophomonas maltophilia non-susceptible to levofloxacin and/or trimethoprim/sulfamethoxazole
- (2019) M Biagi et al. JOURNAL OF CLINICAL MICROBIOLOGY
- In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
- (2019) Ian Morrissey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bacteriophage Therapeutics: A Primer for Clinicians on Phage‐Antibiotic Combinations
- (2019) Taylor Morrisette et al. PHARMACOTHERAPY
- ClpA and HtpX Proteases Are Involved in Intrinsic Aminoglycoside Resistance of Stenotrophomonas maltophilia and Are Potential Aminoglycoside Adjuvant Targets
- (2018) Hsin-Hui Huang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015
- (2018) George G. Zhanel et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Overexpression of Stenotrophomonas maltophilia major facilitator superfamily protein MfsA increases resistance to fluoroquinolone antibiotics
- (2018) Paiboon Vattanaviboon et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests
- (2018) Romney M. Humphries et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17)
- (2018) Helio S Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
- (2018) Michael R. Jacobs et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis
- (2018) J.-H. Ko et al. CLINICAL MICROBIOLOGY AND INFECTION
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Heterogeneous Colistin-Resistance Phenotypes Coexisting in Stenotrophomonas maltophilia Isolates Influence Colistin Susceptibility Testing
- (2018) Sònia Martínez-Servat et al. Frontiers in Microbiology
- Stenotrophomonas maltophilia – a low-grade pathogen with numerous virulence factors
- (2018) Angelina Trifonova et al. Infectious Diseases
- 2419. Standard vs. Alternative Therapy for Stenotrophomonas maltophilia Infections: Focus on Trimethoprim–Sulfamethoxazole, Minocycline, and Moxifloxacin Monotherapy
- (2018) Jasmin Badwal et al. Open Forum Infectious Diseases
- Successful Treatment of Bloodstream Infection Due to Metallo-β-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient
- (2016) Maria F. Mojica et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prevalence of Immunosuppression Among US Adults, 2013
- (2016) Rafael Harpaz et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections
- (2016) Shauna Jacobson et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment ofStenotrophomonas maltophiliainfections
- (2016) Elizabeth Hand et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Increase in the Prevalence of Resistance Determinants to Trimethoprim/Sulfamethoxazole in Clinical Stenotrophomonas maltophilia Isolates in China
- (2016) Li-Fen Hu et al. PLoS One
- Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies
- (2016) Antoine Grillon et al. PLoS One
- The Efflux Pump SmeDEF Contributes to Trimethoprim-Sulfamethoxazole Resistance in Stenotrophomonas maltophilia
- (2015) María Blanca Sánchez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative Genomics of Environmental and ClinicalStenotrophomonas maltophiliaStrains with Different Antibiotic Resistance Profiles
- (2015) Benjamin Youenou et al. Genome Biology and Evolution
- In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives
- (2015) Camila Rizek et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
- (2015) Ya-Ting Chang et al. Frontiers in Microbiology
- A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused byStenotrophomonas maltophilia
- (2015) Chuanqi Wei et al. Infectious Diseases
- Identification of a Novel 6′-N-Aminoglycoside Acetyltransferase, AAC(6′)-Iak, from a Multidrug-Resistant Clinical Isolate of Stenotrophomonas maltophilia
- (2014) Tatsuya Tada et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012
- (2014) Helio S. Sader et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of colistin against Stenotrophomonas maltophilia
- (2014) Carlos Hernan Rodríguez et al. Journal of Global Antimicrobial Resistance
- Involvement of Mutation inampDI,mrcA, and at Least One Additional Gene in β-Lactamase Hyperproduction in Stenotrophomonas maltophilia
- (2013) Asmaa Talfan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Monotherapy with Fluoroquinolone or Trimethoprim-Sulfamethoxazole for Treatment of Stenotrophomonas maltophilia Infections
- (2013) Yu Lin Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Can Levofloxacin Be a Useful Alternative to Trimethoprim-Sulfamethoxazole for Treating Stenotrophomonas maltophilia Bacteremia?
- (2013) Sun Young Cho et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011)
- (2013) Helio S. Sader et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- New strategies againstStenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen
- (2013) Joanna S Brooke Expert Review of Anti-Infective Therapy
- All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials
- (2013) Paul C. McGovern et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens
- (2013) Xavier Wittebole et al. Virulence
- Adverse Effects of Antimicrobials via Predictable or Idiosyncratic Inhibition of Host Mitochondrial Components
- (2012) Alison E. Barnhill et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- NagZ-Dependent and NagZ-Independent Mechanisms for β-Lactamase Expression in Stenotrophomonas maltophilia
- (2012) Yi-Wei Huang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Stenotrophomonas maltophilia Infections in a General Hospital: Patient Characteristics, Antimicrobial Susceptibility, and Treatment Outcome
- (2012) George Samonis et al. PLoS One
- Contribution of Resistance-Nodulation-Division Efflux Pump OperonsmeU1-V-W-U2-Xto Multidrug Resistance of Stenotrophomonas maltophilia
- (2011) Chao-Hsien Chen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical and Microbiologic Outcomes in Trauma Patients Treated forStenotrophomonas maltophiliaVentilator-Associated Pneumonia
- (2011) Quinn A Czosnowski et al. PHARMACOTHERAPY
- Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia
- (2010) Samuel M. Moskowitz et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Community-acquired Stenotrophomonas maltophilia infections: a systematic review
- (2009) M. E. Falagas et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Attributable mortality ofStenotrophomonas maltophiliainfections: a systematic review of the literature
- (2009) Matthew E Falagas et al. Future Microbiology
- Multidrug resistance in clinical isolates of Stenotrophomonas maltophilia: roles of integrons, efflux pumps, phosphoglucomutase (SpgM), and melanin and biofilm formation
- (2009) S.-J. Liaw et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Induction of L1 and L2 -Lactamase Production in Stenotrophomonas maltophilia Is Dependent on an AmpR-Type Regulator
- (2008) A. Okazaki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now